Cocrystal Pharma, INC 8-K filings

Cocrystal Pharma files a corrected version of its auditor's consent to include a reference to the company's effective registration statement on Form S-3.

Cocrystal Pharma announces its 2024 financial results, highlighting progress in its antiviral drug development programs targeting norovirus, influenza, and coronavirus.

Cocrystal Pharma, Inc. presented a corporate update to members of the investment community on January 13, 2025.

Cocrystal Pharma reports favorable safety and tolerability results from a Phase 1 study of its oral antiviral drug CDI-988, intended for the treatment of norovirus and coronavirus infections.

Cocrystal Pharma is extending enrollment in its Phase 2a human challenge study for its influenza drug candidate, CDI-42344, due to unexpectedly low infection rates among participants.

Cocrystal Pharma announced its third quarter 2024 financial results and provided updates on its antiviral drug development programs, including upcoming clinical trial milestones.

Cocrystal Pharma emphasizes its innovative drug discovery platform for developing broad-spectrum antivirals, particularly against emerging influenza and coronaviruses, as the fall season begins.

Cocrystal Pharma's Board of Directors has approved salary increases, bonuses, and stock grants for executive officers and non-employee directors.

Cocrystal Pharma will highlight near-term clinical milestones for its antiviral drug candidates at two upcoming investment conferences.

Cocrystal Pharma reported its second quarter 2024 financial results and provided updates on its antiviral drug development programs, including progress on its influenza and norovirus/coronavirus candidates.

Cocrystal Pharma reports favorable safety and tolerability results from the single-ascending dose cohorts of its Phase 1 study for CDI-988, a potential antiviral treatment for coronaviruses and noroviruses.

Cocrystal Pharma decreased its authorized capital stock and elected six directors at its 2024 Annual Meeting of Stockholders.

Cocrystal Pharma's antiviral drug candidate, CC-42344, has demonstrated in vitro activity against the H5N1 avian influenza strain, including the strain recently identified in infected dairy cows.

Cocrystal Pharma reported its Q1 2024 financial results and provided updates on its antiviral drug development programs, including progress on its influenza and coronavirus/norovirus treatments.

Cocrystal Pharma has completed enrollment in a Phase 2a clinical trial for its oral antiviral candidate CC-42344, targeting pandemic and seasonal influenza A.

Cocrystal Pharma announced its 2023 financial results and provided updates on its antiviral drug development programs, including progress on influenza and coronavirus treatments.

Cocrystal Pharma has received feedback from the FDA on its oral influenza A treatment, CC-42344, providing clarity for its planned Phase 2b trial.

Cocrystal Pharma has terminated its license agreements with Kansas State University Research Foundation, citing futility of further development efforts.